-
House Calls, #951, December 15, 2024: Eli Lilly Levies Fat Tax on Weight Loss Drug
Dr. Yoni Freedhoff joins me today to discuss the decision by Eli Lilly, manufacturer of Mounjaro, to charge more for patients who are suffering with the affects of obesity. In fact the cost will be double that of people using it for the treatment of their type 2 diabetes. Your Calls and Comments:
-
Researchers have found a genetic mutation for hypothyroidism that applies to 1/5000 people and that can lead to increased weight gain. Claims that it is a genetic link to obesity requires some jumping of the hoops.
Medical Mythbusting Commentary for June 25, 2024 Source:Researchers have found a ‘clear genetic trigger for obesity’ that applies to some people Reference: SMIM1 absence is associated with reduced energy expenditure and excess weight
-
Sunday House Call, #909, January 14, 2024: How health insurance company wanna-be-doctor bean counter’s medication-coverage decisions interfere with therapeutic management and has had a deleterious effect on (my) patients’ health outcomes.
I talked about this before yet this continues to be a major issue in that evidence-based medicine is being thwarted by insurance companies’ decision to not provide Semaglutide (Ozempic) for the treatment and management of obesity. It is having a deleterious effect both from a mental and physical health perspective on my patients. Wasn’t the…
-
Sunday House Call, #902, November 19, 2023: The Chosen Ones.
How some pharmacies are deciding that people with type 2 diabetes supersede people with obesity respecting their prescriptions for Ozempic due to shortages. I discuss why this is completely unethical and how other pharmacies are staying away from this bad decision. Your Calls and Comments: